The complex relationship between large granular lymphocyte leukemia and rheumatic disease

Area of Science:

• Hematology
• Immunology
• Rheumatology

Background:

• Large granular lymphocytic (LGL) leukemia is a rare lymphoproliferative disorder involving clonal T or NK lymphocyte expansion.
• Neutropenia-related infections are the primary clinical manifestation, though the disease typically follows an indolent course.
• LGL leukemia frequently co-occurs with autoimmune disorders, most commonly rheumatoid arthritis.

Purpose of the Study:

• To review the pathophysiology, clinic-biological features, and treatment advances in LGL leukemia.
• To highlight the pathophysiological links between LGL leukemia and associated rheumatic disorders.
• To discuss recent molecular insights and their therapeutic implications.

Main Methods:

• Review of current literature on LGL leukemia and associated rheumatic disorders.
• Analysis of phenotypic and molecular characterization of LGL clones.
• Examination of the role of JAK-STAT signaling in disease pathogenesis.

Main Results:

• Recent advances reveal the critical role of JAK-STAT signaling in LGL leukemia cell expansion and autoimmunity.
• The molecular landscape of T- and NK-LGL leukemia is increasingly understood.
• Improved comprehension of associated rheumatic disorders is emerging.

Conclusions:

• Targeted therapies are being developed based on the molecular understanding of LGL leukemia and its associated rheumatic conditions.
• JAK-STAT pathway modulation presents a promising therapeutic strategy for both LGL leukemia and related autoimmune manifestations.
• Further research into the shared pathophysiology can lead to more effective treatment options.